Hikal Reports Mixed Financial Results Amidst Improved Debt Management in June 2025

Hikal, a microcap player in the Pharmaceuticals & Biotechnology industry, has recently reported its financial results for the quarter ending June 2025. The evaluation changes reflect a notable shift in the company's financial standing, with the score experiencing a revision from 23 to -14 over the past three months.
On a positive note, Hikal's debt-equity ratio has reached its lowest point in the last five half-yearly periods at 0.61 times, indicating a reduction in borrowing relative to equity capital. This suggests a strategic move towards strengthening its financial structure.

However, several areas of concern have emerged from the latest financials. The profit before tax less other income (PBT) has shown a significant decline, recorded at Rs -31.40 crore, which is markedly lower than the average of the previous four quarters. Similarly, profit after tax (PAT) has also fallen to Rs -22.40 crore, reflecting a challenging environment for profitability. Net sales have decreased to Rs 380.40 crore, the lowest in the last five quarters, indicating a negative trend in revenue generation. Additionally, the operating profit margin has dropped to 6.60%, highlighting a decline in operational efficiency.

Overall, Hikal's recent financial results indicate a complex landscape, with both positive adjustments in debt management and significant challenges in profitability and sales performance.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.